Sandra D Algaze

Dr. Sandra Algaze is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Southern California focusing on gastrointestinal cancers. Dr. Algaze completed her residency in Internal Medicine at the University of Miami, Jackson Memorial Hospital and her clinical fellowship in Hematology and Oncology at University of Southern California, Los Angeles County Hospital, where she served as a chief fellow.Her research endeavors focus on the discovery of innovative pathways in cancer pathogenesis, metastases and treatment resistance, the development of novel therapies for gastrointestinal tumors, and the assessment of predictive and prognostic biomarkers and molecular profiles. Additionally, she is actively investigating and working to address the complexities surrounding the care of older patients with cancer, and healthcare disparities arising from barriers to specialty care access and the underrepresentation of minorities in cancer clinical trials. Notably, she was part of the inaugural cohort of the Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA).

• Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. Oncogene. 2025 Aug; 44(30):2565-2573.. View in PubMed
• Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 Apr 15; 156(8):1583-1593.. View in PubMed
• Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer. Int J Mol Sci. 2025 Mar 12; 26(6).. View in PubMed
• Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study. J Immunother Cancer. 2024 Nov 05; 12(11).. View in PubMed
• Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist. 2024 Nov 04; 29(11):e1480-e1491.. View in PubMed
• Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review. Cancers (Basel). 2024 Aug 08; 16(16).. View in PubMed
• Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy. Dis Colon Rectum. 2024 Jul 01; 67(7):920-928.. View in PubMed
• Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024 Apr; 201:113914.. View in PubMed
• CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. J Immunother Cancer. 2024 01 11; 12(1).. View in PubMed
• Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions. Oncogene. 2023 02; 42(9):627-637.. View in PubMed
• Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment. Oncogene. 2022 10; 41(43):4769-4778.. View in PubMed
• of Chemotherapy for Solid Tumors. Advance in Cancer Research & Clinical Imaging. 2020; 2(3).
• Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. American Society of Clinical Oncology Educational Book. 2020; e333-e343.
• A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020; 143(3):244-249.. View in PubMed
• Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. BMJ Case Rep. 2018 Mar 09; 2018.. View in PubMed
• The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. Biomedicines. 2017 Nov 29; 5(4).. View in PubMed

• Lenz, Heinz-Josef
• Weitz, Ilene
• Matsuo, Koji
• Zhang, Lin
• Kim, Anthony